Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Liquidia Technologies Inc.

This article was originally published in Start Up

Executive Summary

Liquidia Technologies is developing nanoparticles whose size, shape, particle cargo, and target specificity can be exquisitely controlled. In order to create its particles, Liquidia borrows fabrication methods originally developed by the electronics industry. I
Advertisement

Related Content

Finance Watch: Summer Heat Extends To Biopharma IPOs With Nine In July, 45 This Year
IPO Update: Returns Ride Rollercoaster Into Mid-Year As More Biopharmas Take The Plunge
Tempo Pharmaceuticals Inc.
TransGenex Nanobiotech Inc.
BIND Biosciences Inc.
Nanolymf Ltd.
Start-Up Previews (04/2008)
Nanotechnology: A Balm for the Challenges of Drug Delivery
Nanotechnology: A Balm for the Challenges of Drug Delivery
Start-Up Previews (04/2008)

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC091570

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel